Hyaluronic Acid for Joints & Knee Pain: What Oral Evidence Shows

Oral hyaluronic acid may help some people with knee discomfort, but the joint evidence is not as clean as the skin evidence. Several trials are positive. Others rely on combinations with glucosamine, chondroitin, collagen, krill oil or other ingredients. One direct long-term study found stronger between-group signals mainly in a younger subgroup.

The most important rule is simple: oral HA and intra-articular HA injections are not the same intervention. This article evaluates oral evidence only, except where an injection study is explicitly used as a comparator.

What does the systematic evidence show?

A 2024 systematic review identified 11 oral HA or HA-containing studies across osteoarthritis and low back pain, involving 597 patients. The review was broadly favorable, but the underlying trials were heterogeneous.

That means the headline “11 positive HA studies” would be misleading. Only part of the literature allows a clean conclusion about HA itself. Several interventions contain other active ingredients or combine oral HA with rehabilitation or injections.

Direct oral HA trials

Sugiyama 2023: 111 mg/day

This 12-week double-blind, placebo-controlled trial studied 111 mg/day sodium hyaluronate in adults with knee discomfort. It provides useful direct evidence because HA was the key oral intervention rather than one ingredient buried in a broad joint formula.

Tashiro 2012: 200 mg/day for 12 months

The Tashiro study is valuable because of its unusually long duration. Participants with knee osteoarthritis received 200 mg/day polymer HA or placebo for 12 months. Both groups improved on some measures, while between-group benefit was more apparent in a subgroup aged 70 years or younger.

That is a signal, but subgroup-dependent findings deserve more caution than a clean primary-outcome win across the whole cohort.

Cicero 2020: 200 mg/day

A double-blind randomized trial tested a full-spectrum sodium hyaluronate formulation at 200 mg/day and reported improvements in pain, function and rescue-medication outcomes. It supports the plausibility of oral HA for knee symptoms, but the exact formulation matters when translating the result to other products.

Combination studies: useful but easy to overinterpret

Several oral “HA” joint studies actually test formulations containing HA plus other compounds. Examples in the Data Center include:

• HA with glucosamine and chondroitin;
• HA with krill oil and astaxanthin;
• HA-rich chicken-comb extracts;
• HA with collagen-derived materials;
• oral HA used together with intra-articular HA injections; and
• collagen, vitamin C, sodium hyaluronate and minerals used alongside rehabilitation.

These can tell us whether the formula helped, but not how much of the outcome came from HA.

The null evidence matters

A credible evidence review should include studies that do not fit the sales narrative. In a 2021 randomized trial of a liquid combination of hyaluronan, glucosamine and chondroitin in people with moderate knee pain, the major KOOS, WOMAC and quality-of-life outcomes did not show a clear advantage over placebo.

That does not disprove oral HA. It does show why the overall joint evidence should be described as promising rather than definitive.

What dose is used for joints?

Several of the cleaner direct oral studies fall around 111–200 mg/day. Combination products may contain different amounts or proprietary extracts.

This range is useful when evaluating whether a supplement's label resembles doses used in human trials. It should not be treated as an established treatment dose for osteoarthritis.

See Hyaluronic Acid Dosage for a study-by-study dose map.

How could oral HA affect joints?

HA is a major component of synovial fluid and extracellular matrix, but swallowing HA is not equivalent to putting it directly into the joint. Oral HA is processed through the gastrointestinal tract, and mechanistic work suggests gut microbes play a meaningful role in breaking it down.

Proposed downstream effects include signaling related to inflammation and endogenous HA metabolism, but those mechanisms should not be presented as proof of clinical efficacy. The clinically important question remains whether randomized human outcomes improve.

Oral HA vs hyaluronic acid injections

Evidence supporting one route should not be copied to the other.

What about glucosamine + HA?

Glucosamine and chondroitin frequently appear in HA joint formulas. If someone chooses such a combination, the relevant question is whether that exact formulation has evidence—not whether one ingredient can inherit all benefits observed with another formula.

For SEO and buying decisions, that distinction matters because many product pages cite “hyaluronic acid studies” that actually tested a materially different mixture.

Who should not self-treat knee pain with supplements?

Persistent swelling, locking, instability, inability to bear weight, acute trauma, fever, redness or rapidly worsening pain need medical assessment rather than a supplement experiment. Osteoarthritis also has evidence-based non-supplement strategies including exercise, weight management when appropriate, physical therapy and pharmacologic options.

Bottom line

Oral hyaluronic acid has enough human joint evidence to be taken seriously, but not enough to call it a proven standalone treatment for knee osteoarthritis. Direct studies around 111–200 mg/day are encouraging. The wider literature is weakened by combination products, small samples and inconsistent endpoints.

For the underlying trials—including positive, null and combination studies—see the Hyaluronic Acid Research Data Center.